Quratis and Adult Tuberculosis Vaccines 'advance' in localization


There are venture companies that are focused on establishing vaccine sovereignty.

Quratis, which specializes in new drug development.

Founded last year, Quratis is a venture company of Yonsei Medical Center, and has started to localize vaccines against tuberculosis for adults among them

Currently, Korea has the highest incidence and death rate among the 34 OECD members. The incidence of tuberculosis per 100,000 people is 86, well above the OECD average of 12. The death rate from tuberculosis is also 3.8, more than five times the OECD average.

In this situation, Quratis developed a vaccine for adult tuberculosis from IDRI, a non-profit drug development organization.

IDRI developed 'ID93+GLA-SE', a vaccine developed by the global clinical two-phase Quratis for adult tuberculosis, is developed by fusing selected protein antigen through bioinformatics analysis of tuberculosis bacteria spread all over the world, and is characterized by maintaining stability and purity, which is a strength of subunit vaccine.

Quratis applied for a clinical two-phase test plan late last month with the Ministry of Food and Drug Safety, and plans to launch the product in 2023 after receiving three clinical awards in 2020.

In the process, the company plans to establish a GMP plant for the manufacture of tuberculosis vaccines, and to lay the groundwork for establishing domestic vaccine sovereignty and entering the global market.

Meanwhile, '2017 Bio Health Investment Festival', in which about 30 promising bio and healthcare companies and about 30 venture capital firms prepare to enter the KOSDAQ market in 2018, will hold business presentations as well as one-on-one business meetings.

The event will be held on September 22nd at 9:50 a.m. at the Korea Exchange International Conference Hall and the Public Relations Hall.